Understanding Tysabri and PML: What the Research Shows About Risk Factors

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Awareness to Specific Risk Management

If you or a loved one is taking Tysabri, you may be concerned about the risk of progressive multifocal leukoencephalopathy (PML), a rare but serious brain infection. Decades of pharmacovigilance and clinical research have established a clear link between Tysabri use and PML, with dose and treatment duration being critical risk factors. This page provides an objective overview of the medical evidence, FDA safety communications, and what patients should know about monitoring and risk management.

Understanding Tysabri and Its Association with PML

Tysabri (natalizumab) is a biologic therapy approved for the treatment of multiple sclerosis and Crohn's disease. Its prescribing information carries a boxed warning stating that Tysabri increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain caused by the JC virus (JCV) that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML typically occurs only in patients who are immunocompromised, and its clinical presentation can include progressive neurological deficits such as weakness, cognitive decline, visual disturbances, and coordination problems. Diagnosis is confirmed through brain imaging and detection of JCV DNA in cerebrospinal fluid. The pharmacological mechanism linking Tysabri to PML involves its action as an alpha-4 integrin antagonist. Tysabri blocks the adhesion of immune cells to endothelial surfaces, preventing their migration into the central nervous system. This immunosuppressive effect reduces immune surveillance, allowing latent JCV to reactivate and cause lytic infection of oligodendrocytes, leading to demyelination and the characteristic lesions of PML. Three established risk factors for PML in Tysabri-treated patients are the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered in the context of expected benefit when initiating and continuing treatment.

Legal Considerations and the Statute of Limitations in California

The adequacy of warnings regarding Tysabri and PML is a central issue in legal settlements. The boxed warning explicitly states that Tysabri increases PML risk and that healthcare professionals should monitor patients for any new sign or symptom suggestive of PML, with dosing withheld immediately at the first indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The TOUCH Prescribing Program is a restricted distribution program designed to ensure patients are informed of risks, enrolled, and monitored regularly. Under this program, patients must read the Medication Guide, understand the risks, and sign a Patient Enrollment Form. Healthcare providers must evaluate patients three months after the first infusion, six months after the first infusion, every six months thereafter, and for at least six months after discontinuing Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). They must also determine every six months whether patients should continue treatment and submit status reports to Biogen. Despite these measures, questions may arise about whether patients received adequate information about PML risk, particularly regarding the cumulative nature of risk over time and the significance of anti-JCV antibody status. For affected patients in California, settlement-related considerations involve the statute of limitations, which governs the time frame within which a legal claim must be filed. In California, the statute of limitations for personal injury claims related to pharmaceutical products is generally two years from the date of injury or from when the injury was discovered, or reasonably should have been discovered. The timeline between exposure to Tysabri and documented harm from PML is critical. PML can develop after varying durations of Tysabri treatment, with risk increasing beyond two years of therapy. Symptoms may be subtle initially, and diagnosis can be delayed, complicating the determination of when the injury was discovered. Patients who developed PML after Tysabri use should be aware that the clock for filing a claim may start ticking from the date of diagnosis or from when symptoms became apparent enough to prompt medical investigation. Legal counsel can help assess individual circumstances, including whether the TOUCH program's monitoring requirements were followed and whether any failure to warn contributed to the harm. In summary, Tysabri-associated PML is a severe adverse event with well-documented risk factors and a mandated monitoring program. Patients in California who have been harmed should consider the statute of limitations and seek timely legal advice to preserve their rights. The evidence underscores the importance of early recognition of PML symptoms and adherence to risk mitigation strategies.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri-related PML claims in California?

In California, the statute of limitations for personal injury claims related to pharmaceutical products is generally two years from the date of injury or from when the injury was discovered, or reasonably should have been discovered. For Tysabri-associated PML, the clock may start from the date of diagnosis or when symptoms became apparent enough to prompt medical investigation. It is crucial to consult with legal counsel promptly to preserve your rights.

What are the risk factors for developing PML while on Tysabri?

Three established risk factors for PML in Tysabri-treated patients are the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating and continuing treatment.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Tysabri Prescribing Information (DailyMed)

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.